Forget RNA drugs. Accent gets $40M to develop small molecules that modify RNA instead
A Cambridge startup is stepping out today with some revelations on how proteins tweak RNA — and subsequently how a cell’s character and function is determined. The company, called Accent Therapeutics, scored $40 million in launch money to see if their new tech can deliver precision meds in cancer.
The impetus for the company’s launch is a new understanding of RNA-modifying proteins, and how they might link to disease. Accent’s new findings in the field just got published today in Nature Reviews Drug Discovery.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.